

Dementia: Definition, Overview, and Global Epidemiology

A. Abyad

Consultant, Internal Medicine and Geriatric , Dar Al Shifa Hospital, Kuwait Chairman, Middle-East Academy for Medicine of Aging.

President, Middle East & North Africa Association on Aging & Alzheimer's

Coordinator, Middle-East Primary Care Research Network

Coordinator, Middle-East Network on Aging

Correspondence:

Dr. A. Abyad

Email: aabyad@cyberia.net.lb

Received: August 2025. Accepted: August 2025; Published: September 2025.

Citation: Abyad AA. Dementia: Definition, Overview, and Global Epidemiology. World Family Medicine September 2025; 23(6): 64 - 69.

DOI: 10.5742/MEWFM.2025.805257889

1. Definition and Overview of Dementia

1.1 What is Dementia?

Dementia is a chronic and progressive clinical syndrome caused by various diseases that damage the brain, leading to significant decline in cognitive abilities and loss of functional independence. The term derives from the Latin *demens*, meaning "out of one's mind," though modern understanding emphasizes its neurological basis rather than purely mental illness.

Dementia affects:

- Cognition → memory, language, reasoning, visuospatial skills
- Functionality → ability to perform everyday activities
- Behaviour and personality → mood, emotions, social interactions

Importantly, dementia is not a part of normal aging. While some cognitive changes are typical with age, dementia involves pathological decline beyond normal expectations for a person's age and education level.

1.2 Subtypes of Dementia

Several distinct disorders can cause dementia, each with unique pathological features:

- **Alzheimer's Disease (AD):**
 - Accounts for 60–80% of cases
 - Characterized by amyloid plaques and neurofibrillary tangles
- **Vascular Dementia:**
 - Results from cerebrovascular disease
 - Often follows strokes or chronic small-vessel disease

• **Lewy Body Dementia:**

- Features fluctuating cognition, visual hallucinations, and Parkinsonian symptoms

• **Frontotemporal Dementia (FTD):**

- Prominent changes in personality, behaviour, or language
- Often earlier onset (50s–60s)

Other less common causes include:

- Parkinson's disease dementia
- Huntington's disease
- HIV-associated neurocognitive disorder
- Creutzfeldt-Jakob disease

1.3 Clinical Features

1.3.1 Cognitive Decline

A hallmark of dementia is persistent cognitive impairment. Patients may initially exhibit subtle deficits, progressing to severe disability. Affected domains often include:

- **Memory:** Difficulty recalling recent conversations or events, repeating questions, misplacing items
 - **Language (Aphasia):** Word-finding issues, naming errors, reduced comprehension
 - **Visuospatial Function:** Difficulty recognizing familiar faces, getting lost, misjudging spatial relationships
 - **Executive Function:** Poor planning, difficulty managing finances, impaired decision-making
- These changes are often insidious and progressive, with family members noticing subtle shifts before a formal diagnosis.

1.3.2 Functional Impairment

Unlike normal aging, dementia inevitably affects a person's ability to live independently:

Stage	Functional Changes
Early	Misplacing items, forgetting
Moderate	Needs help dressing, cooking,
Severe	Dependent for basic self-care,

Functional decline impacts:

- Instrumental Activities of Daily Living (IADLs): e.g., managing medications, finances
- Basic Activities of Daily Living (ADLs): e.g., bathing, dressing, eating

Functional deterioration is a significant driver of caregiver burden and institutionalization (Lyketsos et al., 2011).

1.3.3 Behavioural and Psychological Symptoms

Over 80% of dementia patients develop Behavioural and Psychological Symptoms of Dementia (BPSD) during the disease (Lyketsos et al., 2011). These may include:

- Depression
- Anxiety
- Apathy
- Hallucinations
- Delusions
- Wandering
- Agitation or aggression
- Sleep disturbances

Symptoms often fluctuate and may worsen in the evening—a phenomenon known as sundowning.

Example: A patient with Alzheimer's might believe their spouse is an imposter (Capgras syndrome) or insist they need to "go home" despite already being at home.

Management includes:

- Environmental modifications
- Non-pharmacologic interventions (e.g. music therapy, structured activities)
- Judicious pharmacologic treatments when necessary

1.4 Dementia vs. Normal Aging

Differentiating dementia from normal aging is essential for early diagnosis. Key differences include:

Feature	Normal Aging	Dementia
Memory Loss	Misplacing keys, later found	Putting keys in the freezer and forgetting why
Recognition	Occasional name lapses	Not recognizing close family members
Language	Slower word retrieval	Profound language deficits
Functionality	Manages daily life independently	Difficulty performing familiar tasks
Orientation	Preserved	Disorientation in time and place

1.5 Dementia Impact on Patients, Families, and Society

Impact on Patients

- Emotional distress, fear, and anxiety
- Loss of independence and social withdrawal
- Progressive cognitive and physical decline

Impact on Families

- Emotional burden and chronic stress
- Financial strain due to medical costs and caregiving
- Physical health risks among caregivers, including higher rates of depression

Societal Impact

- Global costs exceeded USD 1.3 trillion in 2023, projected to double by 2030
- Workforce impact due to caregiver absenteeism
- Healthcare systems under strain, especially in low- and middle-income countries

Effective dementia policy requires public education, caregiver support, early detection, and investment in research (Prince et al., 2015; Alzheimer's Disease International, 2023).

1.6 Historical Perspectives on Dementia

- **Ancient and medieval eras:** Dementia viewed as moral failing, supernatural influence, or natural aging.
- **18th–19th centuries:**
 - Philippe Pinel differentiated dementia from insanity.
 - “Dementia” became a medical term for irreversible cognitive decline.
- **1906:**
 - Alois Alzheimer described plaques and tangles in a woman with progressive memory loss.
 - Emil Kraepelin named the condition “Alzheimer’s disease.”
- **20th century:**
 - Advances in neuropathology showed dementia as a pathological disease, not normal aging.
- **21st century:**
 - Global health priority.
 - Focus on modifiable risk factors and early intervention (GBD 2019 Dementia Forecasting Collaborators, 2022).

2. Epidemiology of Dementia

2.1 Global Prevalence

Dementia has emerged as a significant public health concern worldwide. As of 2019, approximately 57.4 million people globally were living with dementia (GBD 2019 Dementia Forecasting Collaborators, 2022). This figure is projected to nearly triple to 152.8 million by 2050 (Brookmeyer et al., 2007; Prince et al., 2013; GBD 2019 Dementia Forecasting Collaborators, 2022).

Age-specific prevalence doubles roughly every five years beyond age 65:

Age Group	Prevalence (%)
65–69	1.5–3
70–74	3–6
75–79	6–12
80–84	12–20
≥85	>30

2.2 Gender Differences

Globally, women account for approximately two-thirds of dementia cases (Prince et al., 2015; GBD 2019 Dementia Forecasting Collaborators, 2022). Factors include:

- Women's longer life expectancy
- Possible biological susceptibility
- Social factors (women more likely to live alone and receive diagnosis)

2.3 Regional Variations

Dementia prevalence varies by region, influenced by:

- Age structure
- Life expectancy
- Genetics
- Environmental and lifestyle factors
- Diagnostic practices

Estimated prevalence in people ≥ 60 years:

Region	Estimated Prevalence (%)
North America	~6–8%
Western Europe	~7–9%
Eastern Europe	~5–7%
Latin America	~7–9%
Sub-Saharan Africa	~2–4%
Asia-Pacific	~4–6%
Middle East/North Africa	~4–6%

The largest increases in dementia cases between 2019 and 2050 are projected in:

- North Africa and Middle East (+367%)
- Eastern Sub-Saharan Africa (+357%)

By contrast, increases are smaller in:

- High-income Asia Pacific (+53%)
- Western Europe (+74%)

2.4 Drivers of the Dementia Surge

Population Aging & Growth

Most of the rise in dementia prevalence stems from population aging and growth, rather than significant increases in age-specific dementia rates (GBD 2019 Dementia Forecasting Collaborators, 2022).

Modifiable Risk Factors

Key modifiable risk factors include:

- High BMI
- High fasting plasma glucose
- Smoking
- Low education

While these risk factors slightly increase future dementia burden, education gains may offset some risks. Livingston et al. (2020) estimate that addressing modifiable risks could prevent up to 40% of dementia cases.

2.5 Economic and Social Impact

The economic toll is substantial:

- Global dementia costs exceeded USD 1.3 trillion in 2023, projected to double by 2030 (Alzheimer's Disease International, 2023).

Costs include:

- Direct medical expenses
- Social and institutional care
- Informal caregiving burden

Caregiver burden is significant, encompassing:

- Emotional distress
- Physical exhaustion
- Financial strain

Spouses caring for individuals with dementia are at higher risk for depression and anxiety disorders (Prince et al., 2015).

3. Future Outlook and Challenges

- By 2050, low- and middle-income countries are expected to bear 60–70% of the global dementia burden.
- There is an urgent need for:
 - Early detection programs
 - Public education
 - Dementia-friendly policies
 - Investment in prevention, care innovations, and research into disease-modifying therapies

Conclusion

While age-specific dementia rates are largely stable, **the global burden is set to nearly triple by 2050** due to demographic changes. Preparing health systems, societies, and economies for this surge is a critical challenge.

References

- Alzheimer's Disease International. World Alzheimer Report 2023: Journey through the diagnosis of dementia. London: ADI; 2023.
- Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. (2007). Forecasting the global burden of Alzheimer's disease. *Alzheimer's Dement*, 3(3):186–91.
- Gao S, Hendrie HC, Hall KS, Hui S. (1998). The relationships between age, sex, and the incidence of dementia and Alzheimer disease. *Arch Gen Psychiatry*, 55(9):809–15.
- GBD 2019 Dementia Forecasting Collaborators. (2022). Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050. *Lancet Public Health*, 7(2):e105–e125.
- Langa KM, Larson EB, Crimmins EM, et al. (2017). A comparison of the prevalence of dementia in the United States in 2000 and 2012. *JAMA Intern Med*, 177(1):51–58.
- Livingston G, Huntley J, Sommerlad A, et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*, 396(10248):413–446.
- Lyketsos CG, et al. (2011). Neuropsychiatric symptoms in Alzheimer's disease. *Alzheimer's Dement*, 7(5):532–539.
- Matthews FE, Stephan BCM, Robinson L, et al. (2013). A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England. *Lancet*, 382(9902):1405–12.
- McKhann GM, Knopman DS, Chertkow H, et al. (2011). The diagnosis of dementia due to Alzheimer's disease. *Alzheimer's Dement*, 7(3):263–269.
- Prince M, Wimo A, Guerchet M, et al. (2015). World Alzheimer Report 2015: The Global Impact of Dementia. London: Alzheimer's Disease International.
- Prince M, Wimo A, Guerchet M, et al. (2013). The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimer's Dement*, 9(1):63–75.